JMP Securities downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Outperform to Market Perform saying the path forward to DMD is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE